A multicentre phase II trial of vindesine in malignant melanoma
Carmichael, J.; Atkinson, R.J.; Calman, K.C.; Mackie, R.M.; Naysmith, A.M.; Smyth, J.F.
European Journal of Cancer and Clinical Oncology 18(12): 1293-1295
1982
ISSN/ISBN: 0277-5379 PMID: 6891927 Document Number: 191972
Fifty-three evaluable patients with advanced malignant melanoma were treated with vindesine 3 mg/m2 i.v. weekly for a minimum of 6 wk. An objective response rate of 26% was attained with 17% complete remissions, 78% of which were in stage II disease. The treatment was well tolerated, with alopecia the only clinically significant side-effect (43% of patients). Vindesine is superior to DTIC [5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide] and should be considered as the best currently available drug for malignant melanoma.